OTCMKTS:BXRXV Baudax Bio (BXRXV) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free BXRXV Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$4.51▼$4.5152-Week Range N/AVolume119,000 shsAverage Volume53,220 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Baudax Bio alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Baudax Bio Stock (OTCMKTS:BXRXV)Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… BXRXV Stock News HeadlinesApril 24, 2024 | investing.comBaudax Bio Inc (BXRXQ)March 20, 2024 | morningstar.comBaudax Bio Inc Ordinary Shares BXRXQApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.September 28, 2023 | stockhouse.comBaudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with InhibitorsAugust 23, 2023 | markets.businessinsider.comNoble Financial Remains a Hold on Baudax Bio (BXRX)June 30, 2023 | msn.comWhat's Happening With Baudax Bio Shares TodayJune 30, 2023 | msn.comBaudax Bio Soars on Snapping Up Cell Therapy Developer TeraImmuneJune 30, 2023 | finance.yahoo.comBaudax Bio Acquires TeraImmune, Inc.April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.June 7, 2023 | benzinga.comBaudax Bio Touts Additional Positive Data From Nerve Blocker In Surgery PatientsJune 7, 2023 | technews.tmcnet.comBaudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000June 6, 2023 | finance.yahoo.comBaudax Bio Announces Date of Reconvened Annual MeetingApril 27, 2023 | finanznachrichten.deBaudax Bio, Inc.: Baudax Bio Announces Pricing of $4 Million Public OfferingApril 27, 2023 | msn.comBaudax Bio stock dips on pricing $4M stock offering at $1.15/shareApril 25, 2023 | finance.yahoo.comBaudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000March 27, 2023 | finance.yahoo.comBaudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000January 24, 2023 | finance.yahoo.comWhy Baudax Bio Shares Trading Higher TodayJanuary 24, 2023 | finance.yahoo.comBaudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000January 14, 2023 | seekingalpha.comBXRX Baudax Bio, Inc.December 8, 2022 | finance.yahoo.comBaudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing SurgeryDecember 6, 2022 | nz.finance.yahoo.comBaudax Bio Announces Closing of $5 Million Public OfferingDecember 3, 2022 | finanznachrichten.deBaudax Bio, Inc.: Baudax Bio Announces Pricing of $5 Million Public OfferingDecember 2, 2022 | nz.finance.yahoo.comBaudax Bio Announces Pricing of $5 Million Public OfferingNovember 30, 2022 | yahoo.comBaudax Bio Announces 1-for-40 Reverse Stock SplitNovember 8, 2022 | msn.comBaudax Bio, Inc. (BXRX) Reports Q3 Loss, Lags Revenue EstimatesSeptember 1, 2022 | benzinga.comBaudax Bio Announces Closing of $6.2 Million Public OfferingSeptember 1, 2022 | msn.comHow Is The Market Feeling About Baudax Bio?See More Headlines Receive BXRXV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:BXRXV CUSIPN/A CIKN/A Webwww.baudaxbio.com PhoneN/AFaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors BXRXV Stock Analysis - Frequently Asked Questions How do I buy shares of Baudax Bio? Shares of BXRXV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BXRXV) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baudax Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
